Literature DB >> 26629265

Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting.

Lisa A Raedler.   

Abstract

Entities:  

Year:  2015        PMID： 26629265      PMCID： PMC4665070     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  9 in total

Review 1.  Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.

Authors:  F Roila; J Herrstedt; M Aapro; R J Gralla; L H Einhorn; E Ballatori; E Bria; R A Clark-Snow; B T Espersen; P Feyer; S M Grunberg; P J Hesketh; K Jordan; M G Kris; E Maranzano; A Molassiotis; G Morrow; I Olver; B L Rapoport; C Rittenberg; M Saito; M Tonato; D Warr
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

Review 2.  Update and new trends in antiemetic therapy: the continuing need for novel therapies.

Authors:  P Feyer; K Jordan
Journal:  Ann Oncol       Date:  2010-10-14       Impact factor: 32.976

Review 3.  Chemotherapy-induced nausea and vomiting.

Authors:  Paul J Hesketh
Journal:  N Engl J Med       Date:  2008-06-05       Impact factor: 91.245

Review 4.  Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

Authors:  Ethan Basch; Ann Alexis Prestrud; Paul J Hesketh; Mark G Kris; Petra C Feyer; Mark R Somerfield; Maurice Chesney; Rebecca Anne Clark-Snow; Anne Marie Flaherty; Barbara Freundlich; Gary Morrow; Kamakshi V Rao; Rowena N Schwartz; Gary H Lyman
Journal:  J Clin Oncol       Date:  2011-09-26       Impact factor: 44.544

5.  Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer.

Authors:  Charlotte C Sun; Diane C Bodurka; Candice B Weaver; Rafia Rasu; Judith K Wolf; Michael W Bevers; Judith A Smith; J Taylor Wharton; Edward B Rubenstein
Journal:  Support Care Cancer       Date:  2004-11-09       Impact factor: 3.603

6.  Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy.

Authors:  Ya-Chen Tina Shih; Ying Xu; Linda S Elting
Journal:  Cancer       Date:  2007-08-01       Impact factor: 6.860

7.  Clinical roundtable monograph: New data in emerging treatment options for chemotherapy-induced nausea and vomiting.

Authors:  Gary R Morrow; Rudolph M Navari; Hope S Rugo
Journal:  Clin Adv Hematol Oncol       Date:  2014-03

8.  Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.

Authors:  P J Hesketh; G Rossi; G Rizzi; M Palmas; A Alyasova; I Bondarenko; A Lisyanskaya; R J Gralla
Journal:  Ann Oncol       Date:  2014-03-07       Impact factor: 32.976

9.  A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.

Authors:  M Aapro; H Rugo; G Rossi; G Rizzi; M E Borroni; I Bondarenko; T Sarosiek; C Oprean; S Cardona-Huerta; V Lorusso; M Karthaus; L Schwartzberg; S Grunberg
Journal:  Ann Oncol       Date:  2014-03-05       Impact factor: 32.976
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.